Kory James Wentworth is Chief Financial Officer of Entrada Therapeutics, Inc.. Currently has a direct ownership of 73,849 shares of TRDA, which is worth approximately $1.47 Million. The most recent transaction as insider was on Aug 18, 2022, when has been sold 100 shares (Common Stock) at a price of $2.1 per share, resulting in proceeds of $210. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 73.8K
9.29% 3M change
48.98% 12M change
Total Value Held $1.47 Million

KORY JAMES WENTWORTH Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 18 2022
BUY
Exercise of conversion of derivative security
$210 $2.1 p/Share
100 Added 0.49%
20,441 Common Stock
Aug 17 2022
SELL
Open market or private sale
$2,614 $13.07 p/Share
200 Reduced 0.97%
20,341 Common Stock
Aug 17 2022
BUY
Exercise of conversion of derivative security
$210 $2.1 p/Share
100 Added 0.48%
20,541 Common Stock
Aug 16 2022
SELL
Open market or private sale
$2,600 $13.0 p/Share
200 Reduced 0.97%
20,441 Common Stock
Aug 16 2022
BUY
Exercise of conversion of derivative security
$210 $2.1 p/Share
100 Added 0.48%
20,641 Common Stock
Mar 01 2022
BUY
Grant, award, or other acquisition
-
11,006 Added 34.89%
20,541 Common Stock
KJW

Kory James Wentworth

Chief Financial Officer
Boston, MA

Track Institutional and Insider Activities on TRDA

Follow Entrada Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TRDA shares.

Notify only if

Insider Trading

Get notified when an Entrada Therapeutics, Inc. insider buys or sells TRDA shares.

Notify only if

News

Receive news related to Entrada Therapeutics, Inc.

Track Activities on TRDA